The primary goal is to target activated CTNNB1 pathways or CTNNB1 mutations to induce immune infiltration and/or to target highly expressed VEGF to induce vessel normalisation, thus improving tumour hypoxia and facilitating higher immune infiltration. This evidence concerns the gene VEGFA and neoplasm.